What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Surgery, Chemotherapy and Cancer.
Mark Krailo interconnects Gastroenterology and Sarcoma in the investigation of issues within Internal medicine.
His Oncology research includes elements of Pharmacokinetics, Primitive neuroectodermal tumor, Neuroblastoma, Survival analysis and Acute lymphocytic leukemia.
His Surgery study combines topics from a wide range of disciplines, such as Hepatoblastoma and Urology.
His work in Chemotherapy tackles topics such as Osteosarcoma which are related to areas like Methotrexate, Histological response, Large study, Study groups and Trastuzumab.
The Primary tumor research Mark Krailo does as part of his general Cancer study is frequently linked to other disciplines of science, such as Cog, therefore creating a link between diverse domains of science.
His most cited work include:
- Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. (916 citations)
- ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer (557 citations)
- Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate (499 citations)
What are the main themes of his work throughout his whole career to date?
Mark Krailo mainly investigates Internal medicine, Oncology, Chemotherapy, Surgery and Cancer.
His Internal medicine research incorporates elements of Gastroenterology, Sarcoma and Osteosarcoma.
Many of his research projects under Sarcoma are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His study looks at the intersection of Oncology and topics like Young adult with Pediatrics.
Mark Krailo has researched Surgery in several fields, including Primary tumor and Urology.
The various areas that Mark Krailo examines in his Cancer study include El Niño, Disease and Neuroblastoma.
He most often published in these fields:
- Internal medicine (80.88%)
- Oncology (60.88%)
- Chemotherapy (30.55%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (80.88%)
- Oncology (60.88%)
- Chemotherapy (30.55%)
In recent papers he was focusing on the following fields of study:
Mark Krailo spends much of his time researching Internal medicine, Oncology, Chemotherapy, Osteosarcoma and Germ cell tumors.
His study brings together the fields of Sarcoma and Internal medicine.
The Oncology study combines topics in areas such as Cancer, Clinical trial, Phases of clinical research, Carboplatin and Malignant Germ Cell.
His Chemotherapy study is concerned with the field of Surgery as a whole.
His Surgery study incorporates themes from Carcinoma, Adrenocortical carcinoma and Pediatric malignancy.
His research in Germ cell tumors intersects with topics in Post-hoc analysis, Tumor marker and Confidence interval.
Between 2017 and 2021, his most popular works were:
- Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort (82 citations)
- Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. (27 citations)
- Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. (27 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His main research concerns Internal medicine, Oncology, Osteosarcoma, Chemotherapy and Young adult.
Internal medicine is closely attributed to Sarcoma in his work.
His work deals with themes such as Clinical trial, Phases of clinical research, Carboplatin, Cisplatin and Prospective cohort study, which intersect with Oncology.
Mark Krailo studied Chemotherapy and Hepatoblastoma that intersect with Liver tumor and Percutaneous.
He works mostly in the field of Young adult, limiting it down to concerns involving Cancer and, occasionally, Multivariate analysis, Lung, Histological response and Disease.
His study in Hazard ratio is interdisciplinary in nature, drawing from both Gastroenterology, Ifosfamide, Etoposide and Transplantation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
